Current Report Filing (8-k)
March 23 2017 - 4:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(D) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
|
March 18, 2017
|
Calmare Therapeutics Incorporated
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-08696
|
36-2664428
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1375 Kings Highway East, Fairfield, Connecticut
|
06824
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code:
|
(203) 368-6044
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors
or Principal Officers; Election of Directors; Appointment of Principal Officers.
On March 18, 2017,
Stan Yarbro was removed as a director ("Director") of Calmare Therapeutics, Inc. (the "Company") by a majority
vote of the Board of Directors pursuant to a duly called special meeting of the Board of Directors. Per Article II, Section 2.11
of the Bylaws of the Company, except as may otherwise be provided by the Delaware General Corporation Law, a
ny
director of the Corporation may be removed by a vote of a majority of the Board of Directors in the event such Director has violated
his or her fiduciary duties to the Corporation or has violated the Corporate Code of Conduct as then in effect.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Calmare Therapeutics Incorporated
|
|
|
|
|
|
Date: March 23, 2017
|
By:
|
/s/ Conrad Mir
|
|
|
|
Name: Conrad Mir
|
|
|
|
Title: Chief Executive Officer
|
|
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Apr 2023 to Apr 2024